Autres langues Appili Therapeutics Inc.

Actions

APLI

CA03783R1073

Marché Fermé - Toronto S.E. Autres places de cotation 17:26:30 02/05/2024			Varia. 5j.	Varia. 1 janv.
0,035 ^CAD	0,00%		-12,50%	0,00%

13/02	Appili Therapeutics Inc. annonce ses résultats pour le troisième trimestre et les neuf mois terminés le 31 décembre 2023	CI
2023	Appili Therapeutics Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 30 septembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Appili Therapeutics Inc. announced that it has received CAD 0.3 million in funding	26/04
Appili Therapeutics Signs Definitive Agreement to be acquired by Aditxt, Inc.	03/04
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense	03/04
Appili Therapeutics To be Acquired by Aditxt, Inc.	02/04
Adivir, Inc. entered into a definitive agreement to acquire Appili Therapeutics Inc. for $6.7 million.	02/04
Appili Therapeutics Notes Researchers Publish Manuscript on Prevention and Emergency Response to Tularemia Outbreaks	12/03
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks	12/03
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024	13/02
Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan	18/12
Appili Therapeutics Says Patent Issued For Biodefence Vaccine Candidate ATI-1701, Provides Update on Bridge Loan	15/12
Appili Therapeutics Brief: Announcing Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Providing Update on Bridge Loan	15/12
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan	15/12
Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	14/11
Appili Therapeutics Inc. Appoints Prakash Gowd to its Board of Directors	14/11
Appili Therapeutics Q2 Net Loss and Comprehensive Loss Narrows Vs a Year Ago	13/11
Appili Therapeutics Brief: As of September 30, 2023, Co had cash of $0.4 million, compared to $2.5 million on March 31, 2023.	13/11
Appili Therapeutics Brief: Net loss and comprehensive loss of $1.0 million or $0.01 loss per share for the Three months ended September 30, 2023	13/11
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024	13/11
Appili Therapeutics Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy	26/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Appili Therapeutics Inc.

Actions

APLI

CA03783R1073

Autres langues

Filtres